Editing C3 Glomerulopathy (MGRS)

{{tp|p=24671835|t=2014. C3 glomerulopathy: una rivoluzione nella classificazione delle glomerulonefriti.|pdf=|usr=}}{{24671835}}
{{tp|p=28356669|t=2017. C3 glomerulopathy associated to multiple myeloma successfully treated by autologous stem cell transplant.|pdf=|usr=}}{{28356669}}
{{tp|p=27994856|t=2016. C3 glomerulopathy in adults: a distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome.|pdf=|usr=}}{{27994856}}
{{tp|p=24357668|t=2014. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation.|pdf=|usr=}}{{24357668}}
{{tp|p=33774080|t=2021. Proliferative Glomerulonephritis With Fibrils, Monoclonal kappa Light Chain, and C3 Deposits.|pdf=|usr=}}{{33774080}}
{{tp|p=30474593|t=2019. Corticosteroid therapy alone for the treatment of C3 glomerulonephritis in association with monoclonal gammopathy .|pdf=|usr=}}{{30474593}}
{{tp|p=38076230|t=2023. C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis.|pdf=|usr=}}{{38076230}}
{{tp|p=37724175|t=2023. Daratumumab in the treatment of C3 glomerulopathy with monoclonal gammopathy: a case report and literature review.|pdf=|usr=}}{{37724175}}
{{tp|p=37363300|t=2023. Immunoelectron microscopy findings in a patient with C3 glomerulonephritis.|pdf=|usr=}}{{37363300}}
{{tp|p=37189718|t=2023. Diagnostic Problems in C3 Glomerulopathy.|pdf=|usr=}}{{37189718}}
{{tp|p=36899849|t=2023. Diagnostic and Prognostic Comparison of Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.|pdf=|usr=}}{{36899849}}
{{tp|p=36631797|t=2023. Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study.|pdf=|usr=}}{{36631797}}
{{tp|p=35777834|t=2022. Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis.|pdf=|usr=}}{{35777834}}
{{tp|p=35223908|t=2022. Case Report: Chronic Lymphocytic Leukemia With Recurrent Complement-Mediated Thrombotic Microangiopathy and C3 Glomerulonephritis.|pdf=|usr=}}{{35223908}}
{{tp|p=34703825|t=2021. Complete Renal Recovery in Pediatric Patient with C3 Glomerulonephritis: A Case Report.|pdf=|usr=}}{{34703825}}
{{tp|p=34616577|t=2021. Mycoplasma pneumoniae Infection Associated C3 Glomerulopathy Presenting as Severe Crescentic Glomerulonephritis.|pdf=|usr=}}{{34616577}}
{{tp|p=34456924|t=2021. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.|pdf=|usr=}}{{34456924}}
{{tp|p=34211499|t=2021. CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.|pdf=|usr=}}{{34211499}}
{{tp|p=34023209|t=2021. Treatment of Monoclonal Gammopathy-associated C3 Glomerulopathy With Daratumumab-based Therapy.|pdf=|usr=}}{{34023209}}
{{tp|p=32943008|t=2020. C3-glomerulonephritis in New Zealand - a case series.|pdf=|usr=}}{{32943008}}
{{tp|p=32816888|t=2020. Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease.|pdf=|usr=}}{{32816888}}
{{tp|p=32695788|t=2020. Diverse Clinical Presentations of C3 Dominant Glomerulonephritis.|pdf=|usr=}}{{32695788}}
{{ttp|p=31823738|t=2019. Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis.|pdf=|usr=}}{{31823738}}
{{tp|p=31384438|t=2019. Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy.|pdf=|usr=}}{{31384438}}
{{ttp|p=30487789|t=2018. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.|pdf=|usr=}}{{30487789}}
{{ttp|p=30333829|t=2018. Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy.|pdf=|usr=}}{{30333829}}
{{tp|p=30186495|t=2018. Complement 3 glomerulonephritis in rheumatoid arthritis: A case report and follow-up.|pdf=|usr=}}{{30186495}}
{{tp|p=29724174|t=2018. Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft.|pdf=|usr=}}{{29724174}}
{{tp|p=29594148|t=2018. C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction.|pdf=|usr=}}{{29594148}}
{{tp|p=29329521|t=2018. Treating C3 glomerulopathy with eculizumab.|pdf=|usr=}}{{29329521}}
{{ttp|p=29166869|t=2017. Multimodal imaging of retinal pigment epithelial detachments in patients with C3 glomerulopathy: case report and review of the literature.|pdf=|usr=}}{{29166869}}
{{tp|p=28573137|t=2017. Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.|pdf=|usr=}}{{28573137}}
{{tp|p=28357053|t=2017. C3 glomerulopathy.|pdf=|usr=}}{{28357053}}
{{tp|p=27878657|t=2017. C3 glomerulopathy and current dilemmas.|pdf=|usr=}}{{27878657}}
{{tp|p=27274824|t=2016. Kidney transplant outcomes in familial C3 glomerulopathy.|pdf=|usr=}}{{27274824}}
{{tp|p=27200326|t=2016. Overview of C3 Glomerulopathy.|pdf=|usr=}}{{27200326}}
{{tp|p=26251715|t=2015. Timing of eculizumab therapy for C3 glomerulonephritis.|pdf=|usr=}}{{26251715}}
{{tp|p=26251714|t=2015. Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis.|pdf=|usr=}}{{26251714}}
{{tp|p=26069834|t=2013. Recovery of renal function succeeding stem cell transplant: a case of C3 Glomerulonephiritis secondary to monoclonal gammopathy.|pdf=|usr=}}{{26069834}}
{{tp|p=24178974|t=2014. C3 glomerulopathy: clinicopathologic features and predictors of outcome.|pdf=|usr=}}{{24178974}}
{{tp|p=22403278|t=2012. Eculizumab for dense deposit disease and C3 glomerulonephritis.|pdf=|usr=}}{{22403278}}
{{tp|p=21784830|t=2011. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association?|pdf=|usr=}}{{21784830}}
{{tp|p=37176142|t=2023. Clinico-Pathogenic Similarities and Differences between Infection-Related Glomerulonephritis and C3 Glomerulopathy.|pdf=|usr=}}{{37176142}}
{{tp|p=36938068|t=2023. C3 Glomerulopathy and Thrombotic Microangiopathy: A "Hybrid" Phenotype.|pdf=|usr=}}{{36938068}}
{{ttp|p=36751667|t=2022. C3 Glomerulopathy: A Review with Emphasis on Ultrastructural Features.|pdf=|usr=}}{{36751667}}
{{tp|p=34520493|t=2021. Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry.|pdf=|usr=}}{{34520493}}
{{tp|p=33840955|t=2020. Clinico-pathological Profile and Outcome of C-3 Glomerulopathy in Indian Children.|pdf=|usr=}}{{33840955}}
{{tp|p=33615080|t=2021. Efficacy of Eculizumab in Coexisting Complement C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome.|pdf=|usr=}}{{33615080}}
{{tp|p=33305125|t=2020. Long-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children.|pdf=|usr=}}{{33305125}}
{{tp|p=33096866|t=2020. Treatment of C3 Glomerulopathy in Adult Kidney Transplant Recipients: A Systematic Review.|pdf=|usr=}}{{33096866}}
{{tp|p=32518880|t=2020. Use of Bortezomib in the Treatment of C3 Glomerulonephritis Refractory to Eculizumab and Rituximab.|pdf=|usr=}}{{32518880}}
{{tp|p=31980588|t=2020. CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.|pdf=|usr=}}{{31980588}}
{{tp|p=31919107|t=2020. Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy.|pdf=|usr=}}{{31919107}}
{{ttp|p=31703608|t=2019. C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy.|pdf=|usr=}}{{31703608}}
{{tp|p=31701048|t=2019. Glomerular Complement Factor H-Related Protein 5 (FHR5) Is Highly Prevalent in C3 Glomerulopathy and Associated With Renal Impairment.|pdf=|usr=}}{{31701048}}
{{tp|p=30993226|t=2019. Transplant Glomerulopathy With Glomerular C3 Deposits: Why the Worse Outcome?|pdf=|usr=}}{{30993226}}
{{ttp|p=30692664|t=2019. C3 glomerulopathy - understanding a rare complement-driven renal disease.|pdf=|usr=}}{{30692664}}
{{tp|p=32734182|t=2019. C3 Glomerulonephritis: A Rare Etiology of the Pulmonary Renal Syndrome.|pdf=|usr=}}{{32734182}}
{{tp|p=30369521|t=2018. Predictive factors for poor outcome in pediatric C3 glomerulonephritis.|pdf=|usr=}}{{30369521}}
{{ttp|p=30077216|t=2018. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.|pdf=|usr=}}{{30077216}}
{{ttp|p=29729982|t=2018. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.|pdf=|usr=}}{{29729982}}
{{tp|p=29030465|t=2018. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.|pdf=|usr=}}{{29030465}}
{{tp|p=28210641|t=2017. Atypical Plasmacytic Proliferation in a Case of C3 Glomerulopathy: Pathophysiology Demystified.|pdf=|usr=}}{{28210641}}
{{tp|p=27631242|t=2016. C3 glomerulonephritis in multiple myeloma: A case report and literature review.|pdf=|usr=}}{{27631242}}
{{tp|p=26471127|t=2016. A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H.|pdf=|usr=}}{{26471127}}
{{tp|p=26374608|t=2016. Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.|pdf=|usr=}}{{26374608}}
{{tp|p=25991042|t=2015. C4d Staining in the Diagnosis of C3 Glomerulopathy.|pdf=|usr=}}{{25991042}}
{{tp|p=25991041|t=2015. C4d as a Diagnostic Tool in Proliferative GN.|pdf=|usr=}}{{25991041}}
{{tp|p=25684865|t=2015. Incidence and profile of C3 Glomerulopathy: A single center study.|pdf=|usr=}}{{25684865}}
{{tp|p=25484526|t=2014. Current concepts in C3 glomerulopathy.|pdf=|usr=}}{{25484526}}
{{tp|p=24172683|t=2013. C3 glomerulopathy: consensus report.|pdf=|usr=}}{{24172683}}
{{ttp|p=23907509|t=2013. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy.|pdf=|usr=}}{{23907509}}
{{tp|p=23689905|t=2013. Eculizumab and recurrent C3 glomerulonephritis.|pdf=|usr=}}{{23689905}}
{{tp|p=23479095|t=2013. Recent insights into C3 glomerulopathy.|pdf=|usr=}}{{23479095}}
{{tp|p=23204401|t=2013. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis.|pdf=|usr=}}{{23204401}}
{{tp|p=22677550|t=2012. Pathology after eculizumab in dense deposit disease and C3 GN.|pdf=|usr=}}{{22677550}}
{{ttp|p=22673887|t=2012. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.|pdf=|usr=}}{{22673887}}
{{tp|p=22157657|t=2012. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.|pdf=|usr=}}{{22157657}}
{{tp|p=34658305|t=2021. C3 glomerulonephritis associated with monoclonal gammopathy: a retrospective case series study from a single institute in China.|pdf=|usr=}}{{34658305}}
{{tp|p=33482806|t=2021. C3 glomerulonephritis along with light chain proximal tubulopathy without crystal deposits in multiple myeloma: a case report.|pdf=|usr=}}{{33482806}}
{{tp|p=27458560|t=2016. Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.|pdf=|usr=}}{{27458560}}
{{tp|p=27500215|t=2015. Atypical Hemolytic Uremic Syndrome Recurrence after Renal Transplantation: C3-Glomerulonephritis as an Initial Presentation.|pdf=|usr=}}{{27500215}}
{{tp|p=24161036|t=2013. Dense deposit disease and C3 glomerulopathy.|pdf=|usr=}}{{24161036}}